Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.37 |
| ▸ | PPARA | Q07869 | 4/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3849410 | 0.96 | PPARG (0.40) | PPARGPPARAS1PR2S1PR4S1PR1 | |
| SCHEMBL3844324 | 0.93 | PPARG (0.38) | PPARGPPARAS1PR2S1PR4S1PR1 | |
| SCHEMBL3841112 | 0.91 | PPARG (0.39) | PPARGPPARAPPARDTP53ADORA3 | |
| SCHEMBL3841397 | 0.91 | PPARG (0.32) | PPARGPPARAS1PR2S1PR4S1PR1 | |
| SCHEMBL3842931 | 0.91 | PPARA (0.43) | PPARGPPARAPPARDTP53ADORA3 | |
| SCHEMBL3840711 | 0.91 | MAOA (0.33) | PPARGPPARAS1PR2S1PR4S1PR1 | |
| SCHEMBL3840985 | 0.89 | PPARG (0.36) | PPARGPPARAS1PR2S1PR4S1PR1 | |
| SCHEMBL3284391 | 0.88 | PPARA (0.38) | PPARGPPARATP53ADORA3 | |
| SCHEMBL3849869 | 0.87 | PPARG (0.38) | PPARGPPARAS1PR2S1PR4S1PR1 | |
| SCHEMBL3842355 | 0.87 | PPARG (0.41) | PPARGPPARAPPARDTP53ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856065-B1 | 1,2,4-TRIAZINE DERIVATIVES, PREPARATION AND USE THEREOF IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2009-11-11 | — | — | EP | claimed |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | PIERRE FABRE MEDICAMENT (FR) | 2008-07-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | CBR3, NOX3, RTN3 | PPARG 2530/4885PPARA 3384/4885S1PR2 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.